Cell Death and Disease (Aug 2024)

The feedback loop between MTA1 and MTA3/TRIM21 modulates stemness of breast cancer in response to estrogen

  • Jingyao Zhang,
  • Yinuo Wang,
  • Jingjing Zhang,
  • Xin Wang,
  • Jiaxiang Liu,
  • Miaomiao Huo,
  • Ting Hu,
  • Tianyu Ma,
  • Die Zhang,
  • Yu Li,
  • Chang Guo,
  • Yunkai Yang,
  • Min Zhang,
  • Baowen Yuan,
  • Hao Qin,
  • Xu Teng,
  • Tianyang Gao,
  • Xinhui Hao,
  • Hefen Yu,
  • Wei Huang,
  • Binghe Xu,
  • Yan Wang

DOI
https://doi.org/10.1038/s41419-024-06942-w
Journal volume & issue
Vol. 15, no. 8
pp. 1 – 15

Abstract

Read online

Abstract The metastasis-associated protein (MTA) family plays a crucial role in the development of breast cancer, a common malignancy with a high incidence rate among women. However, the mechanism by which each member of the MTA family contributes to breast cancer progression is poorly understood. In this study, we aimed to investigate the roles of MTA1, MTA3, and tripartite motif-containing 21 (TRIM21) in the proliferation, invasion, epithelial-mesenchymal transition (EMT), and stem cell-like properties of breast cancer cells in vivo and in vitro. The molecular mechanisms of the feedback loop between MTA1 and MTA3/TRIM21 regulated by estrogen were explored using Chromatin immunoprecipitation (ChIP), luciferase reporter, immunoprecipitation (IP), and ubiquitination assays. These findings demonstrated that MTA1 acts as a driver to promote the progression of breast cancer by repressing the transcription of tumor suppressor genes, including TRIM21 and MTA3. Conversely, MTA3 inhibited MTA1 transcription and TRIM21 regulated MTA1 protein stability in breast cancer. Estrogen disrupted the balance between MTA1 and MTA3, as well as between MTA1 and TRIM21, thereby affecting stemness and the EMT processes in breast cancer. These findings suggest that MTA1 plays a vital role in stem cell fate and the hierarchical regulatory network of EMT through negative feedback loops with MTA3 or TRIM21 in response to estrogen, supporting MTA1, MTA3, and TRIM21 as potential prognostic biomarkers and MTA1 as a treatment target for future breast cancer therapies.